Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT05917054 |
Other study ID # |
2/2021.K-66 |
Secondary ID |
|
Status |
Completed |
Phase |
|
First received |
|
Last updated |
|
Start date |
January 1, 2021 |
Est. completion date |
January 1, 2023 |
Study information
Verified date |
June 2023 |
Source |
Istinye University |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Observational [Patient Registry]
|
Clinical Trial Summary
The usage of vessel sealing devices has been gaining popularity in all surgical specialties.
Post-renal transplant drain placement is a common practice among transplant surgeons.
However, prolonged drainage accompanied by surgical wound complications and perirenal fluid
collections is a frequent complication experienced by the recipients. This study aimed to
compare bipolar sealing with conventional back-table dissection in terms of post-renal
transplant drainage duration, amount, surgical wound complication, and back-table preparation
time.
Description:
Consecutive recipients receiving a living donor kidney transplant at Istinye University Organ
Transplantation Center will be enrolled in this study. Istinye University Hospital Ethical
Review Committee approved the clinical study (2/2021.K-66). Informed consent will be obtained
from all individual participants included in this study. The recipients will be randomized
into two groups by a simple randomization (i.e., flipping coin) method. In Group 1, bipolar
sealing method will be used, and in Group 2, conventional silk tie ligature will be used
during the back-table dissections of the harvested grafts. Data parameters including
recipient age, gender, body mass index (BMI), cause of end-stage renal disease, dialysis
modality, postoperative pain, surgical drainage duration, back-table time, cold ischemia
time, and surgical site infections will be collected on a database by a research nurse. The
exclusion criteria will be pediatric recipients and recipients who had received a kidney
transplant previously. The donor nephrectomies will be performed using a pure laparoscopic
technique. A standard right/left lower Gibson incision will be made in every recipient, and
the renal bed will be prepared extraperitoneally. The external iliac vein and external iliac
artery will be used for graft vessel anastomosis. Lymphatic vessels will be tied by 3/0 and
2/0 silk sutures in the conventional group, whereas bipolar sealing method will be used in
the other.
Study investigators will be blinded to patient randomizations. All vascular anastomoses and
bladder-ureter anastomoses will be performed by the primary surgeon (E.E). One closed-suction
Hemovac drain will be placed at the lower pole of the graft in all recipients, and it will be
removed when discharge is less than 50 ml over 24 hours. The Gregoir-Lich anti-reflux
anastomosis technique performed all ureteroneocystostomies with Polydioxanone (PDS) sutures.
A double J stent will be inserted in all cases. A Foley catheter will also be placed in the
bladder and removed on the fourth postoperative day as recommended in the literature. All
patients will be evaluated for pain on the postoperative 1 st day. The pain will be assessed
with a visual analog scale, scoring from 0 to 10, with 0 being no pain and 10 being the worst
pain ever experienced. Triple immunosuppression with tacrolimus, mycophenolate mofetil, and
steroid will be initiated on post-renal transplant day 1 to all recipients. In addition,
high-risk recipients will receive thymoglobulin as induction, while low-risk recipients will
receive Basiliximab on days 0 and 4 post-transplant. All recipients will be anticoagulated by
daily subcutaneous enoxaparin 0,6 cc injections starting on the day of surgery until the day
of discharge. Patients will be followed in terms of pain, drainage length, and wound
complications for 6 months. Surgical wounds will be assessed daily during the post-transplant
1 st week, then weekly afterward.